L Benjamin
GlaxoSmithKline
16 Papers
11 Citations
L Benjamin is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 8, co-authored 16 publications. Previous affiliations of L Benjamin include University of Paris & EHESP.
Chat about Author
Papers
Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS)
Stefan Andreas,Christos Chouaid,Sarah Danson,Obukohwo Siakpere,L Benjamin,Rainer Ehness,Marie-Hélène Dramard-Goasdoue,Janina Barth,Hans Hoffmann,Vanessa Potter,Fabrice Barlesi,Costel Chirila,Kelly Hollis,Carolyn Sweeney,Mark Price,Sorrel Wolowacz,James A. Kaye,Ilias Kontoudis +17 more
TL;DR: This is the first comprehensive study describing the burden of illness for patients with completely resected stage IB-IIIA NSCLC and the economic burden was substantial in all three countries.
55
Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.
Christos Chouaid,Sarah Danson,Stefan Andreas,Obukohwo Siakpere,L Benjamin,Rainer Ehness,Marie-Hélène Dramard-Goasdoue,Janina Barth,Hans Hoffmann,Vanessa Potter,Fabrice Barlesi,Mark Price,Costel Chirila,Kelly Hollis,Carolyn Sweeney,Sorrel Wolowacz,James A. Kaye,Ilias Kontoudis +17 more
TL;DR: A high rate of first recurrence with distant metastatic disease was observed in patients with complete resection of stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom, emphasising the need for more effective systemic adjuvant therapies in this population.
36
Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data.
Rana Maroun,Rana Maroun,L. Mitrofan,L Benjamin,Gaëlle Nachbaur,Franck Maunoury,Philippe Le Jeunne,Isabelle Durand-Zaleski +7 more
TL;DR: Treatment patterns appeared to follow current practice guidelines and PFS results were higher than those observed in clinical trials, which seems to be consistent with findings from other real world studies.
Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts
TL;DR: It is discussed how the HPS in France and USA may generate disincentives to the use of OADs in certain circumstances, and how drug reimbursement systems and hospital financing changes should contribute to improve equal and safe patient access to appropriate anticancer drugs and improve the management and care pathway of cancer patients.
In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013
TL;DR: In-hospital costs of managing mRCC are mainly driven by expensive drugs and inpatient costs, and analysis of the determinants of prescribing expensive drugs at hospital did not show social or territorial differences in the use of these drugs.